Chugai Pharmaceutical Co., LTD.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.9Mgeneral payments (2019-2025)
$4,060research payments (2019-2025)
349clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $314K
2020 $78K
2021 $134K
2022 $107K
2023 $317K
2024 $444K
2025 $479K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Hematology & Oncology $398K
Medical Oncology $283K
Internal Medicine $171K
Urology $155K
Gastroenterology (Internal Medicine) $147K
Neurology (Psychiatry & Neurology) $105K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Andrew Von Eschenbach Montgomery, TX Urology $142,521.04
Joseph Murray Rochester, MN Gastroenterology (Internal Medicine) $126,273.36
Bruce Chabner Boston, MA Internal Medicine $118,456.16
David Avigan Boston, MA Hematology & Oncology $89,244.98
Naoto Ueno Honolulu, HI Medical Oncology $87,539.00
Norman Sharpless Chapel Hill, NC Hematology & Oncology $78,824.14
Christopher Flowers Houston, TX Hematology & Oncology $69,751.94
Richard Finn Santa Monica, CA Hematology & Oncology $46,067.18
Benjamin Greenberg Dallas, TX Neurology (Psychiatry & Neurology) $42,339.50
Steven Pipe Ann Arbor, MI Pediatric Hematology-Oncology $34,667.81

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.